

Dactinomycin (Actinomycin D)

Dactinomycin, or actinomycin D, is an antitumor antibiotic used to treat childhood tumors. It is indicated for use against Wilms tumor, Ewing's sarcoma, rhabdomyosarcoma, and gestational trophoblastic malignancy. It works by intercalating DNA and halting the replication process in tumors. A common side effect of this drug is myelosuppression.



PLAY PICMONIC

Indications

Wilms' Tumor

Willy-Wonkey the Tumor-guy

Dactinomycin is indicated to treat Wilms' tumor, or nephroblastoma, which is a childhood tumor of the kidneys.

Rhabdomyosarcoma

Raptor-mayo-shark-comb

Dactinomycin can be used in conjunction with radiation therapy to treat rhabdomyosarcoma, a sarcoma of skeletal muscle. Rhabdomyosarcoma is more common in children and often affects very early forms of muscle cells. Common sites include the head, neck, urinary and reproductive organs, limbs, and trunk (chest and abdomen).

Ewing's Sarcoma

Earring-shark-comb

Ewing's sarcoma is a malignant bone cancer affecting teenagers and young adults. Ewing's sarcoma is treated using neoadjuvant therapy, where dactinomycin is combined with radiation therapy.

Gestational Trophoblastic Malignancy

Pregnant Trophy-blast Malignant-man

This medication can be used to treat gestational trophoblastic malignancy, such as malignant hydatidiform moles.

Mechanism

Intercalates DNA

Inner-cleats DNA

This drug works by intercalating into DNA, effectively inhibiting its transcription. It does so by binding to the DNA transcription initiation complex and prevents RNA chain elongation. Dactinomycin effectively "gets in the way," physically blocking RNA transcription.

Side Effect

Myelosuppression

Suppressed Red and White blood cells

The most common side effect of dactinomycin is myelosuppression, which leads to decreased red and white blood cell production.